Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCL

Video

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Traditionally in DLBCL, physicians expected 15% to 20% of patients to be alive at the 2-year mark. Now, with the emergence of CAR T-cell therapy, researchers expect approximately 40% of patients to be alive at the 2-year mark. This is encouraging because a survival of at least 2 years indicates long-term survival, Maziarz says. However, that still leaves 60% of patients who need effective therapy. Therefore, a better understanding of what drives resistance is crucial.

Moreover, CAR T-cell therapy is associated with unique toxicities, and researchers need to make the treatment safer so more patients can receive it. For example, a proliferation event can occur as a result of cells growing fast.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.